Related Experiment Video
Updated: Oct 23, 2025
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
The impact of COVID-19 on the sensitivity of D-dimer for pulmonary embolism
Samuel J Elberts1, Ryan Bateman1, Alexandra Koutsoubis2
1Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Insights
D-dimer testing for pulmonary embolism (PE) showed similar sensitivity in COVID-19 patients compared to those without the virus. This suggests D-dimer may be a reliable indicator for PE in both patient groups.
Area of Science:
- Emergency Medicine
- Infectious Diseases
- Cardiology
Background:
- Pulmonary embolism (PE) is a critical diagnosis often evaluated using D-dimer testing.
- The impact of COVID-19 on the diagnostic performance of D-dimer for PE remains an area of active investigation.
- Understanding D-dimer's utility in COVID-19 patients is crucial for accurate and timely PE diagnosis.
Purpose of the Study:
- To evaluate the test characteristics of D-dimer for diagnosing pulmonary embolism (PE) in patients with concurrent COVID-19.
- To compare the sensitivity of D-dimer for PE in COVID-19-positive versus COVID-19-negative patients.
- To assess the potential for D-dimer to rule out PE in patients with COVID-19.
Main Methods:
- A multicenter retrospective observational cohort study was conducted.
- Data from 1158 patient encounters with computed tomography pulmonary angiography (CTPA), D-dimer, and COVID-19 testing were analyzed.
- Test characteristics (sensitivity, specificity, NPV) and receiver operating characteristic (ROC) curves were calculated for D-dimer assays.
Main Results:
- D-dimer testing demonstrated similar performance for PE detection in COVID-19-positive and -negative patients.
- In COVID-19-positive patients, sensitivity was 100% and negative predictive value (NPV) was 100%.
- Adjusting D-dimer thresholds on ROC curves showed potential to increase specificity while maintaining 100% sensitivity for both assays.
Conclusions:
- Concomitant COVID-19 infection did not significantly alter the sensitivity of D-dimer for pulmonary embolism.
- Further research is needed to confirm if D-dimer alone can safely exclude PE in COVID-19 patients.
- Investigating adjusted D-dimer levels may offer improved management strategies for PE in the context of COVID-19.
Objective:
This study seeks to evaluate the test characteristics of D-dimer for pulmonary embolism (PE) in patients with a concurrent diagnosis of COVID-19. We hypothesized that the sensitivity of D-dimer for PE at current institutional cut points would be similar to those without COVID-19.
Methods:
This is a multicenter retrospective observational cohort study across five urban and suburban EDs in the same health care system. The electronic health record was queried for all computed tomography pulmonary angiography (CTPA) studies from December 1, 2019, to October 22, 2020. All ED patients who underwent CTPA had D-dimer and COVID-19 testing completed in a single encounter were included in the study. Baseline demographics were obtained. Test characteristics of D-dimer for PE were calculated for patients with and without COVID-19. Additionally, receiver operator characteristics (ROC) curves were constructed for two different D-dimer assays.
Results:
There were 1158 patient encounters that met criteria for analysis. Performance of D-dimer testing for PE was similar between COVID-19-positive and -negative patients. In COVID-19-positive patients, the sensitivity was 100% (95% confidence interval [CI] = 87.6%-100%), specificity was 11.9% (95% CI = 7.9%-17.1%), and negative predictive value (NPV) was 100%. In COVID-19-negative patients the sensitivity was 97.6% (95% CI = 91.5%-99.7%), specificity was 14.4% (95% CI = 12.1%-17%), and NPV was 98.3% (95% CI = 93.8%-99.6%). For assay 1 the area under the curve (AUC) for COVID-19-positive patients was 0.76 (95% CI = 0.68-0.83), and for COVID-19-negative patients, 0.73 (95% CI = 0.69-0.77). For assay 2, AUC for COVID-19-positive patients was 0.85 (95% CI = 0.77-0.92), and for COVID-19-negative patients, 0.80 (95% CI = 0.77-0.84). Inspection of the ROC curve for assay 1 revealed that 100% sensitivity was maintained up to a threshold of 0.67 FEU (fibrinogen equivalent units; from 0.50 FEU) with an increase in specificity to 29% (from 18.7%), and for assay 2, 100% sensitivity was maintained up to a threshold of 662 D-dimer units (DDU; from 230 DDU) with an increased specificity to 59% (from 6.1%).
Conclusion:
Results from this multicenter retrospective study did not find a significant difference in sensitivity of D-dimer for PE due to concomitant COVID-19 infection. Further study is required to determine if PE can safely be excluded based on D-dimer results alone in patients with suspected or proven COVID-19 or if adjusted D-dimer levels could have a role in management.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29Pulmonary Embolism I: Introduction
01:27Pulmonary Embolism III: Nursing Management
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...